Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry
分析了美国风湿病登记数据中，不同保险支付者和医疗机构在英夫利西单抗生物类似药的新患者启动和从原研药转换上的差异，发现医疗补助和私人保险的新用户使用率高于医疗保险，且转换率普遍较低，机构差异解释了大部分变异。
OBJECTIVE: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally. STUDY SETTING AND DESIGN: Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching. Key variables of interest include insurance payer and practice. DATA SOURCES AND ANALYTIC SAMPLE: Secondary analysis of 37,560 patients aged ≥18 years administered infliximab (bio-originator or biosimilar) between April 2016 and September 2022 in Rheumatology Informatics System for Effectiveness. We tested for differences in use of biosimilar infliximab by demographic characteristics, socioeconomic status, and diagnosis using standard mean differences and multivariable modified Poisson regression. We used generalized estimating equations to assess the adjusted effect of insurance and year of initiation on new biosimilar starts. We analyzed variation in biosimilar switching by insurance, date of switch, and practice. PRINCIPAL FINDINGS: A total of 8196 (21.8%) infliximab users ever used a biosimilar and use did not differ significantly by demographic or clinical characteristics. In 2022, uptake among new users was higher among those with Medicaid (55%; 95%CI 43%-68%) and private insurance (51%; 95%CI 46%-57%) compared to Medicare (36%; 95%CI 29%-43%). Few prevalent bio-originator infliximab users switched to a biosimilar, and switching was lowest among Medicare beneficiaries (7% vs. 14.2% in Medicaid and 16.9% among privately insured). In adjusted analyses, practice level differences explained 37% of variation among new biosimilar starts and 34% of variation among those switching to a biosimilar. CONCLUSIONS: Our findings underscore two critical areas for enhancing biosimilar infliximab usage: increasing switching among prevalent users and increasing uptake among Medicare beneficiaries initiating treatment. Significant variation in uptake across practices also suggests that local switching policies are likely key drivers of uptake.